Dyne Therapeutics Inc (DYN) - Total Assets
Based on the latest financial reports, Dyne Therapeutics Inc (DYN) holds total assets worth $1.08 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dyne Therapeutics Inc - Total Assets Trend (2007–2025)
This chart illustrates how Dyne Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see DYN company net worth for the company's overall valuation and market capitalisation.
Dyne Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Dyne Therapeutics Inc's total assets of $1.08 Billion consist of 94.9% current assets and 5.1% non-current assets. Review DYN total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Dyne Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Dyne Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dyne Therapeutics Inc's current assets represent 94.9% of total assets in 2025, an increase from 12.6% in 2007.
- Cash Position: Cash and equivalents constituted 75.3% of total assets in 2025, up from 2.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Dyne Therapeutics Inc Competitors by Total Assets
Key competitors of Dyne Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Dyne Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.92 | 20.35 | 31.70 |
| Quick Ratio | 19.92 | 20.35 | 31.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $969.78 Million | $655.62 Million | $446.75 Million |
Dyne Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Dyne Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.55 |
| Latest Market Cap to Assets Ratio | 2.49 |
| Asset Growth Rate (YoY) | 71.7% |
| Total Assets | $1.19 Billion |
| Market Capitalization | $2.96 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Dyne Therapeutics Inc's assets at a significant premium (2.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Dyne Therapeutics Inc's assets grew by 71.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual total assets of Dyne Therapeutics Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.19 Billion | +71.72% |
| 2024-12-31 | $691.23 Million | +318.72% |
| 2023-12-31 | $165.08 Million | -46.11% |
| 2022-12-31 | $306.32 Million | -28.04% |
| 2021-12-31 | $425.66 Million | +20.47% |
| 2020-12-31 | $353.33 Million | +2049.76% |
| 2019-12-31 | $16.44 Million | +98.79% |
| 2018-12-31 | $8.27 Million | -99.93% |
| 2017-12-31 | $11.77 Billion | -9.82% |
| 2016-12-31 | $13.05 Billion | +13.12% |
| 2015-12-31 | $11.54 Billion | +2.73% |
| 2014-12-31 | $11.23 Billion | +112.29% |
| 2013-12-31 | $5.29 Billion | +16.67% |
| 2012-12-31 | $4.54 Billion | +9.89% |
| 2011-12-31 | $4.13 Billion | -58.78% |
| 2010-12-31 | $10.01 Billion | -8.58% |
| 2009-12-31 | $10.95 Billion | -22.94% |
| 2008-12-31 | $14.21 Billion | +7.50% |
| 2007-12-31 | $13.22 Billion | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more